Sanofi US Services Inc.
$114.0M 478 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Edge Endo LLC
Edge Endo LLC reported $113,381,790.44 across General Payments, Research, and Ownership to 40 physicians and teaching hospitals across 41 transactions.
- $113.4M Top 10% payer
- All-tracks total
- 41 Below-median volume
- Transactions
- 40 Below-median reach
- Recipients
- +$91.0M
- General Payments vs PY2023
Edge Endo LLC reported $113,381,790.44 across all CMS Open Payments tracks (General + Research + Ownership) to 40 physicians and teaching hospitals in Program Year 2024 - ranking #22 of 1,925 reporting manufacturers (0.8% of the all-tracks industry total); General Payments alone were $91,139,126.87, averaging $2.8M per recipient.
How Edge Endo LLC's $113.4M all-tracks total breaks down
Edge Endo LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
39/100
Total payments
A
100/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer edge-endo-llc Edge Endo LLC
$113.4M · #22/1,925 · 0.8% industry · PY2024
- TOT $113.4M
- RANK #22
- SHARE 0.8%
- TXN 41
- RCP 40
- CAT 3
- GEN $91.1M
- ΔGEN +$91.0M
- TOP1 99.9%
- PY 2024
Volume peers
Nearest volume peer: Sanofi US Services Inc. ($114.0M)
Edge Endo LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Edge Endo LLC's CMS-reported General Payments increased by $91.0M (+94043.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: EDGE ENDO LLCPY2023: EDGE ENDO LLCPY2024: Edge Endo LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $96,808.88
- PY2024
- $91,139,126.87
What the Data Shows for Edge Endo LLC
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Edge Endo LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
1 transactions worth $91.1M make "Acquisitions" the top general-payment category in the 3-category breakdown below, 99.9% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Edge Endo LLC made 3 types of general payments. "Acquisitions" is the largest category at $91.1M, 99.9% of General Payments.
How Edge Endo LLC divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Acquisitions | $91.1M | 1 | 99.9% |
| Consulting Fee | $45.5K | 15 | 0.0% |
| Long-Term Medical Supply or Device Loan | $10.9K | 24 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $91,133,626.87 (100.0%) of $91,139,126.87 in this company's General Payments records across 9 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Edge Endo LLC
The five named recipients with the highest reported General Payments from this company
- 1
Charles Goodis
$91,082,706.03 across 1 reported transactions
- 2
Justin Kolnick
$28,550.87 across 19 reported transactions
- 3
Charles Maupin
$11,042.88 across 13 reported transactions
- 4
George Goodis
$7,327.09 across 1 reported transactions
- 5
Frederic Barnett
$4,000.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Edge Endo LLC's spend rank (#22 of 1,925, top 1% by spend) and concentration rank (#132 of 1,838, top 7% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Midwest Medical Resources Inc : $1.0K total payments, HHI 10000
- Genesis Innovation Group, Inc. : $136.00 total payments, HHI 10000
- Jcbd, LLC : $65.3K total payments, HHI 10000
- Diagnostic Green GmbH : $36.0K total payments, HHI 10000
- Pixee Medical Inc. : $601.00 total payments, HHI 10000
- InSightec,LTD : $865.8K total payments, HHI 9998
- Edge Endo LLC (this company) : $91.1M total payments, HHI 9988
- Ikon Spine LLC : $120.5K total payments, HHI 9985
- BioNTech SE : $180.6M total payments, HHI 9959
- Caption Health, Inc. : $7.5K total payments, HHI 9935
- Aptis Medical, LLC : $1.2M total payments, HHI 9916
- Global Kinetics USA Corporation : $52.4K total payments, HHI 9914
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Edge Endo LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Edge Endo LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Edge Endo LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Trimed, Inc.
$111.0M 2,318 recipients
Compare payment profiles
Vertex Pharmaceuticals Incorporated
$109.6M 10,996 recipients
Compare payment profiles
Arthrex, Inc.
$109.0M 49,842 recipients
Compare payment profiles
Regeneron Pharmaceuticals, Inc.
$123.5M 5,932 recipients
Compare payment profiles
AstraZeneca UK Limited
$124.7M 2,367 recipients
Compare payment profiles
Put this to use
Edge Endo LLC ranks #22 of 1,925 by all-tracks total payments, led by "Acquisitions".
- See where Edge Endo LLC sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Acquisitions" spend across every manufacturer, not just Edge Endo LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.